Plant Sources Anti-Cancer Agents Market to Reach US$ 14.45 Billion by 2033 at 10.5% CAGR; North America Leads with 40% Share | Key Players Pfizer, TAPI (Teva), Fresenius Kabi

The Plant Sources Anti-Cancer Agents market was valued at US$ 6.92 billion in 2024 and is expected to reach US$ 14.45 billion by 2033, growing at a CAGR of 10.5% during the forecast period 2025-2033. Market growth is driven by rising prevalence of cancer globally, increasing demand for safer and effective therapeutic options, and expanding research into bioactive compounds derived from plants such as vincristine, paclitaxel, camptothecin, and podophyllotoxin. These naturally derived agents are widely used in oncology treatment regimens due to their proven anti-tumor activity and lower toxicity profiles compared with some synthetic drugs.

The market is gaining momentum from ongoing clinical research, bioprospecting of novel phytochemicals, and partnerships between pharmaceutical companies and research institutions aimed at identifying and commercializing new plant-based anti-cancer agents. Increased investments in natural product drug discovery, improved extraction technologies, and supportive regulatory frameworks for botanical therapeutics are strengthening pipeline development. North America holds the largest market share due to advanced oncology infrastructure, strong research funding, and early adoption of plant-derived therapies, while Asia-Pacific is the fastest-growing region, driven by rich biodiversity, expanding biomedical research capabilities, and growing healthcare investments; Europe continues steady growth supported by established pharmaceutical innovation ecosystems.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/plant-sources-anti-cancer-agents-market?sai-v

The Plant Sources Anti-Cancer Agents market refers to the sector focused on bioactive compounds derived from plants that are used in the development of cancer prevention and treatment therapies.

Key Developments
✅ January 2026: In North America, research and development of plant-derived anti-cancer agents expanded within academic and biotech sectors, with institutions and companies such as MD Anderson Cancer Center, Stanford University School of Medicine, Eisai Inc., and AbbVie advancing preclinical pipelines of plant-derived compounds (e.g., taxanes, vinca alkaloids, camptothecins) and AI-guided natural product discovery to improve efficacy and reduce treatment toxicity.

✅ January 2026: In Europe, pharmaceutical and research collaborations-including AstraZeneca, Novartis, Karolinska Institutet, and German Cancer Research Center (DKFZ)-boosted screening of botanical libraries and phenotypic assays to identify novel bioactive plant metabolites with anti-proliferative and apoptotic activities in solid tumors and hematologic malignancies.

✅ December 2025: In Asia-Pacific, increased investments in ethnobotanical research and traditional medicine integration accelerated exploration of anticancer properties in plant compounds by Takeda Pharmaceutical, Himalaya Wellness, Shanghai Institute of Materia Medica (CAS), and Kyowa Hakko Kirin, focusing on flavonoids, terpenoids, and alkaloids for combination therapy development.

✅ December 2025: Globally, integration of computational biology, high-throughput screening, and systems pharmacology improved identification and optimization of novel plant-derived anti-cancer agents, with contributions from IBM Watson Health, Schrödinger, Exscientia, and natural product biotech startups enhancing lead selection and SAR (structure-activity relationship) modeling.

✅ November 2025: In Latin America, collaborative research initiatives between universities and industry groups such as Instituto Nacional de Cancerología (Mexico), Fiocruz (Brazil), and Universidad de Buenos Aires identified region-specific plant bioactives with potential anti-tumor properties, strengthening translational research frameworks.

✅ October 2025: Worldwide, rising interest in combination therapies incorporating plant-derived compounds with immunotherapies and targeted therapies advanced clinical trial designs, with academic and industry sponsors exploring synergistic regimens to enhance response rates and overcome resistance mechanisms.

Mergers & Acquisitions
✅ January 2026: Eisai Co., Ltd. acquired PhytoCure BioSciences, a biotechnology company focused on discovery and development of plant-derived small molecules with anti-cancer activity, to strengthen its oncology portfolio and expand natural product-based drug development platforms.

✅ December 2025: Takeda Pharmaceutical Company acquired HerbaThera Oncology, a specialist in plant metabolite-based therapeutic candidates, to augment its research capabilities in novel anticancer agents and accelerate early-stage clinical programs.

✅ November 2025: BioVectra (a Lonza Company) acquired Nature's Oncology Labs, a developer of scalable botanical extraction and semi-synthetic modification technologies for natural anticancer compounds, to enhance its supply chain and formulation expertise in plant-derived therapeutic ingredients.

Key Players
Phyton Biotech | ScinoPharm | Samyang | Novasep | Huiang Biopharma | TAPI (Teva) | Fresenius Kabi | Pfizer | West-Ward Pharmaceuticals | Jiangsu Yew Biotechnology | Others

Key Highlights
Pfizer holds 24% market share, driven by its strong API manufacturing capabilities, global regulatory approvals, and vertically integrated pharmaceutical supply chain.

TAPI (Teva) accounts for 20% market share, supported by its large-scale active pharmaceutical ingredient production, broad generic portfolio, and extensive customer base across regulated markets.

Fresenius Kabi represents 14% market share, leveraging its expertise in complex APIs, injectables, and strong presence in hospital and specialty pharmaceuticals.

ScinoPharm holds 11% market share, driven by its strengths in high-potency APIs, advanced synthesis technologies, and compliance with international quality standards.

Novasep captures 9% market share, supported by its focus on complex molecules, custom manufacturing services, and strong footprint in innovative and specialty APIs.

Phyton Biotech accounts for 7% market share, benefiting from its plant-based API production technologies and leadership in botanical and fermentation-derived compounds.

Samyang holds 6% market share, driven by its diversified chemical and pharmaceutical ingredient portfolio and growing exports to global markets.

Huiang Biopharma represents 5% market share, supported by its cost-competitive API manufacturing and expanding reach in emerging pharmaceutical markets.

West-Ward Pharmaceuticals and Jiangsu Yew Biotechnology together account for 3% market share, focusing on specialty APIs, intermediates, and contract manufacturing services.

Other players collectively hold 1% market share, comprising regional API manufacturers and emerging biotechnology firms.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=plant-sources-anti-cancer-agents-market?sai-v

(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Market Drivers
- Increasing global cancer incidence and rising demand for safer, effective therapeutic options driving research and development of plant-derived anti-cancer agents.

- Growing interest in natural and bioactive compounds with potential anti-tumor properties, including alkaloids, flavonoids, terpenoids, and phenolics from medicinal plants.

- Expanding scientific evidence and clinical research supporting efficacy of plant-based compounds in cancer prevention, adjunct therapy, and drug discovery.

- Advancements in phytochemistry, high-throughput screening, and molecular biology enhancing identification, isolation, and optimization of plant-based anti-cancer agents.

- Rising investments by pharmaceutical and biotech companies in botanical drug research, combined with supportive government and academic collaborations accelerating innovation.

Industry Developments
- Integration of AI, cheminformatics, and computational modeling to rapidly screen plant metabolite libraries for anti-cancer activity and optimize lead compounds.

- Development of standardized extraction, purification, and formulation technologies to improve bioavailability, stability, and therapeutic outcomes of plant-derived agents.

- Strategic partnerships between research institutions, pharmaceutical firms, and traditional medicine experts to explore ethnobotanical sources and validate medicinal potential.

- Emergence of novel plant-based anti-cancer drugs entering preclinical and clinical evaluation, including targeted phytochemicals and combination therapies.

- Expansion of bio-resource banks, botanical libraries, and compound databases to support discovery pipelines and accelerate translational research.

Regional Insights
North America - 40% share: "Driven by advanced oncology research infrastructure, robust clinical trial activity, strong biotech investment, and high adoption of natural product drug discovery."

Europe - 28% share: "Supported by increasing focus on integrative oncology research, collaboration between academic centers and industry, and regulatory frameworks facilitating botanical drug development."

Asia Pacific - 22% share: "Fueled by rich biodiversity, traditional medicinal knowledge, expanding research capabilities, and growing pharmaceutical R&D spending."

Latin America - 6% share: "Driven by vast plant biodiversity, emerging natural product research initiatives, and collaborations to identify anti-cancer phytochemicals."

Middle East & Africa - 4% share: "Supported by developing research infrastructure, increasing interest in traditional medicine validation, and growing investment in cancer research."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/plant-sources-anti-cancer-agents-market?sai-v

By Type
Paclitaxel holds a major share due to its extensive use across multiple solid tumors and its established efficacy in combination therapies. Vinorelbine is widely used in breast and lung cancer treatment, supported by favorable tolerability profiles. Irinotecan plays a critical role in advanced and metastatic cancers, particularly in combination regimens. Hydroxycamptothecin is gaining traction due to ongoing research and expanding clinical applications. Docetaxel remains a key chemotherapy agent, especially in breast, prostate, and lung cancers, while other drug types include emerging formulations and generics supporting broader accessibility.

By Application
Breast cancer represents the largest application segment, driven by high global prevalence and strong clinical adoption of taxane-based therapies. Ovarian cancer follows closely, supported by standard chemotherapy protocols incorporating these drugs. Cervical cancer applications are growing steadily, particularly in developing regions with improving access to oncology treatments. Other applications include lung, colorectal, and gastric cancers, contributing to overall market expansion.

By Distribution Channel
Hospital pharmacies dominate the market due to the injectable nature of most anticancer drugs and the need for supervised administration. Retail pharmacies account for a growing share, supported by oral formulations and supportive oncology medications. Online pharmacies are emerging gradually, driven by increasing digital health adoption and patient convenience. Other distribution channels include specialty oncology clinics and government supply programs supporting cancer care initiatives.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.